STATEMENT ON 22ND DRUG COMPANY REFUSING TO OFFER 340B DRUG PRICING; NOVO NORDISK FURTHER RESTRICTS 340B CONTRACT PHARMACY PRICING
WASHINGTON, D.C.—Two global drug manufacturers, Novo Nordisk and Organon, announced yesterday new restrictions on 340B pricing. Organon, the 22nd drug company to impose restrictions on 340B hospitals, unveiled a policy that limits 340B pricing exclusively to locations registered as 340B covered entities. Meanwhile, Novo Nordisk announced further tightening of its already restrictive 340B policy. These disruptive moves come in the wake of similar actions taken by Amgen, Pfizer, GSK and Johnson & Johnson. 340B Health holds serious concerns regarding the tightening of 340B pricing restrictions by pharmaceutical companies, as evidenced by these repressive actions. The following statement is attributed to Maureen Testoni, president and CEO of 340B Health:
“It's disappointing that Novo Nordisk and Organon have adopted policies that further limit safety-net hospitals from serving low-income patients and underserved rural communities. These policies hinder access to essential healthcare, perpetuating existing disparities. We urge a reconsideration for the well-being of vulnerable populations. As we await decisions from two appeals courts, we remain committed to urging the Biden administration to vigorously defend its interpretation of the 340B law.”
Contact: Jon Tilton at jon.tilton@340bhealth.org or 202-536-2285